Genprex

Monthly Archives: December 2018

Genprex to Launch Investors Website and Increase Emphasis on Investor Relations in 2019

Company Placing Priority on Investor Engagement with New Website, Email Updates

AUSTIN, Texas & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dec. 12, 2018– Genprex, Inc. (NASDAQ: GNPX) a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that it will be increasing its investor relations efforts in 2019, spearheaded by the launch of an innovative corporate website with more robust investor resources, including the company’s presentations, stock charts and integrated quotes, SEC filings, news, media coverage, and tailored email newsletters, among other advanced communication tools….

Read More

Genprex to Present at the 11th Annual LD Micro Main Event

Presentation Wed., Dec. 5, 2018, at 10:30 a.m. PST

AUSTIN, Texas & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dec. 3, 2018– Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that its Chairman and Chief Executive Officer, Rodney Varner, will present at the 11th annual LD Micro Main Event at the Luxe Sunset Boulevard Hotel in Los Angeles, CA….

Read More